All Clinical Trials

Clinical Trial NCT05678959

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

  • ClinicalTrials.gov ID: NCT05678959
  • Recruiting participants (Starts Jun. 30, 2023)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: JOHN ANDREW BIRD

objective

To evaluate the long-term safety and tolerability of ligelizumab in participants with food allergy

Participate

If you are interested in this clinical trial, please contact Melissa Zamudio on the Children’s Health Research Team.Call 214-456-5711Email